News Pfizer acquires Therachon and its dwarfism drug Pfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is developing treatments for a form
News UCB buys cell therapy biotech Candid for $2bn upfront Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
